Search
Items ($0.00)   View Cart Checkout

Numedica Mag-Plex Ultra - 240c

BrandNumedica
Price
$39.90
SKUNM337
Qty

Numedica Mag-Plex Ultra - 240c features the highly absorbable magnesium lysyl glycinate chelate and the patented di-magnesium malate from Albion® Advanced Nutrition, the world leader in patented mineral amino acid chelate and organic mineral acid complex research and development. NuMedica® has chosen Albion® Advanced Nutrition’s mineral technology to provide the highest quality minerals for optimal absorption and utilization. 

Magnesium is involved in over 300 enzyme-related processes including cardiac, muscle and nerve function and the production of ATP for energy.* Magnesium also plays a role in supporting optimal bone density and maintenance of blood glucose levels.
One Capsule Contains:
 
Magnesium ................................................... 125 mg
  (TRAACS® magnesium lysyl glycinate chelate and  
  di-magnesium malate)  
 
Other Ingredients: HPMC (vegetable capsule), MCC (microcrystalline cellulose), rice flour, ascorbyl palmitate, silica.
 
Contains No: Milk, egg, fish, shellfish, wheat, tree nuts, peanuts, soy, corn, yeast, animal products, artificial colors, sweeteners or preservatives.
 
TRAACS and The Albion Medallion design are registered trademarks of Albion Laboratories, Inc. Malate covered by Albion International, Inc. U.S. Patent 6,706,904 and patents pending.
 
Directions: Take one capsule 2-3 times daily between meals or as directed by your healthcare practitioner.

About the Manufacturer

NuMedica offers the highest quality nutraceuticals manufactured to meet or exceed strict cGMP quality standards. We have pioneered the development of innovative, science-based nutritional supplements that are prescribed by thousands of licensed healthcare practitioners around the world. NuMedica prides itself on setting the standard for the highest quality, innovative nutritional formulas in the professional marketplace.

2002-2018 Integrative Psychiatry All rights reserved.
Stay Connected: Facebook Twitter